Frontier Biotechnologies Inc banner
F

Frontier Biotechnologies Inc
SSE:688221

Watchlist Manager
Frontier Biotechnologies Inc
SSE:688221
Watchlist
Price: 19 CNY 0.74% Market Closed
Market Cap: ¥7.1B

Cash Flow Statement

Cash Flow Statement
Frontier Biotechnologies Inc

Rotate your device to view
Cash Flow Statement
Currency: CNY
Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025
Operating Cash Flow
Stock-Based Compensation
0
0
0
2
0
0
0
0
0
0
0
0
0
Cash Taxes Paid
27
51
49
54
45
8
8
6
1
(0)
(0)
(4)
(5)
Change in Working Capital
(163)
(114)
(101)
(334)
(387)
(443)
(488)
(319)
(313)
(297)
(300)
(283)
(275)
Cash from Operating Activities
(277)
N/A
(259)
+7%
(273)
-5%
(289)
-6%
(323)
-12%
(344)
-6%
(312)
+9%
(267)
+14%
(242)
+9%
(196)
+19%
(191)
+2%
(173)
+10%
(177)
-3%
Investing Cash Flow
Capital Expenditures
(400)
(305)
(216)
(140)
(139)
(120)
(108)
(129)
(68)
(60)
(58)
(19)
(26)
Other Items
273
659
821
23
222
96
226
302
(159)
59
(474)
(172)
205
Cash from Investing Activities
(127)
N/A
354
N/A
605
+71%
(117)
N/A
83
N/A
(25)
N/A
118
N/A
173
+46%
(227)
N/A
(1)
+100%
(532)
-50 296%
(191)
+64%
179
N/A
Financing Cash Flow
Net Issuance of Debt
283
234
224
(14)
(11)
(31)
(51)
101
82
98
95
109
55
Cash Paid for Dividends
(6)
(6)
(14)
(15)
(18)
(20)
(14)
(14)
(15)
(16)
(16)
(15)
(13)
Other
(35)
(30)
165
188
184
144
(10)
(16)
(9)
33
(8)
(8)
(7)
Cash from Financing Activities
242
N/A
198
-18%
375
+89%
159
-57%
155
-3%
93
-40%
(76)
N/A
70
N/A
59
-16%
115
+95%
70
-39%
86
+21%
35
-60%
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
(0)
(0)
(0)
0
0
(0)
Net Change in Cash
(162)
N/A
294
N/A
707
+141%
(247)
N/A
(85)
+66%
(276)
-224%
(269)
+2%
(24)
+91%
(410)
-1 593%
(83)
+80%
(653)
-691%
(278)
+57%
36
N/A
Free Cash Flow
Free Cash Flow
(677)
N/A
(564)
+17%
(488)
+13%
(429)
+12%
(463)
-8%
(464)
0%
(420)
+10%
(397)
+6%
(310)
+22%
(257)
+17%
(249)
+3%
(191)
+23%
(203)
-6%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett